Research Study

 
News Articles for Research Study top ^
Latest Data Sweep from a 285 Patient Subgroup Shows An Impressive 57% Improvement in Overall Survival Data Continues to Validate Phase III OPTIMA Study Design LAWRENCEVILLE, N.J. , July 28, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced updated results from its retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC). As of June 30, 2014 , the latest quarterly Overall Survival (OS) analysis demonstrated that in a large, well bounded, subgroup of patients (n=285, 41% of the study patients), the combination of ThermoDox® and optimized RFA provided a 57% improvement in OS compared to optimized RFA alone.
Sign-up for Celsion Announces Updated Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver Cancer investment picks
Kyungpook National University Hospital in South Korea Treats the First Patient in the 14 Country, 100 Site Global Study Study Designed to Support Registration in Major Liver Cancer Markets Worldwide LAWRENCEVILLE, N.J. , Sept.
Sign-up for Celsion Announces Enrollment of First Patient in Global Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer investment picks
Last Patient Completes 18-Month Primary Treatment Period - Top-Line Data on Track to Report in 3Q14 96% of Patients with Amenable Mutations Elected to Continue in 12-Month Treatment Extension Statistical Analysis Plan Finalized CRANBURY, N.J., June 30, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) , a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today provided updates and detailed the statistical analysis plan for its second Phase 3 study ( Study 012 ) of the oral small molecule pharmacological chaperone migalastat HCl ("migalastat") monotherapy for Fabry patients with amenable mutations.
Sign-up for Amicus Therapeutics Provides Updates and Final Analysis Plan for Phase 3 Fabry Monotherapy Study 012 investment picks
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that two Phase 3 clinical trials (Studies 104 and 111) evaluating an investigational once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults met their primary objectives.
Sign-up for Gilead’s Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies investment picks
2014/8/25
ENGLEWOOD, Colo.
Sign-up for Letter to the Ampio Shareholders in Regard to the STEP Study and Ampio's plans for the Ampion™ BLA investment picks
IRVINGTON, N.Y., July 24, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA) , developer of the MelaFind ® system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced new study results demonstrating the effectiveness of MelaFind predictive probability information when used by dermatology residents.
Sign-up for MELA Sciences Announces New Study Results Demonstrating Improved Diagnostic Accuracy for Resident Dermatologists When Utilizing MelaFind Predictive Probability Information investment picks
Migalastat Successfully Meets Both Co-Primary Endpoints of Comparability to Enzyme Replacement Therapy (ERT) on Both Key Measures of Kidney Function CRANBURY, N.J., Aug.
Sign-up for Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012 investment picks
2014/9/11
OceanaGold announces preliminary results of the Didipio Optimisation Study Canada NewsWire /NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES AND NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES./ (All figures in US Dollars unless otherwise stated) MELBOURNE , Sept.
Sign-up for OceanaGold announces preliminary results of the Didipio Optimisation Study investment picks
LOS ANGELES, July 8, 2014 (GLOBE NEWSWIRE) -- RadNet Inc. (Nasdaq:RDNT) , a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 250 owned and/or operated outpatient imaging centers, announced it has joined a research study, the Imaging and Genetic Biomarkers for Alzheimer's Disease (ImaGene) study.
Sign-up for RadNet Joins UCLA-Easton Center Alzheimer's Disease Research Study investment picks
Study Results Presented at the Alzheimer's Association International Conference 2014 INDIANAPOLIS , July 16, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data showing that beta-amyloid imaging was associated with altered diagnosis and management of patients with Alzheimer's disease.
Sign-up for New Study Shows Beta-Amyloid Imaging is Associated with Altered Diagnosis and Management of Alzheimer's Disease investment picks
Study Achieved Primary Endpoint of Predicting Recurrence after Surgery and Reconfirmed Original Adverse Pathology Endpoint from Published UCSF Validation Study Data Submitted for Presentation at Medical Meeting Later this Year REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Positive Topline Results of Additional, Large Independent Validation Study of Oncotype DX® Prostate Cancer Test with Multiple Clinical Endpoints investment picks
Yellowhead Mining Inc. Files Feasibility Study on SEDAR Canada NewsWire VANCOUVER , Sept.
Sign-up for Yellowhead Mining Inc. Files Feasibility Study on SEDAR investment picks
First Patient Dosed in the EU Post-Authorization Safety Study First Patient Dosed in the Phase 1 Study in Adolescent Patients MOUNTAIN VIEW, Calif.
Sign-up for Alexza Pharmaceuticals Provides an Update on the Five Post-EMA Approval Studies for ADASUVE® investment picks
2014/7/15
Women surveyed said they are taking control of household finances, yet are no more prepared to make financial decisions than they were a decade ago, according to new research released today by Prudential Financial, Inc. The study, which is Prudential’s eighth biennial study of women and money, revealed women are less concerned about their financial security than after the 2008 financial crisis.
Sign-up for Prudential study finds women feel less confident in their ability to save and invest investment picks
Clovis Oncology (NASDAQ:CLVS) today announced preliminary Phase 2 results from the ARIEL2 ( A ssessment of R ucaparib I n Ovarian Canc e r Tria l ) study and updated results from the ongoing Phase 1/2 monotherapy study of rucaparib.
Sign-up for Data from Ongoing Phase 2 Studies of Rucaparib in Ovarian Cancer Demonstrate Safety and Clinical Activity, Validate Differentiated Strategy investment picks
Results from First Clinical Study Using NGS-based Proprietary Liquid Biopsy Platform to Detect Presence of Breast Cancer Also Will Be Presented REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Oral Presentation of Positive Results from Second Large, Independent Clinical Validation Study of Oncotype DX® in DCIS Breast Cancer at 2014 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) investment picks
2014/9/24
Schwab Advisor Services released the results from a first-of-its kind survey today examining the career paths of independent registered investment advisors (RIAs) and the attributes of the profession that attract talent into its ranks.
Sign-up for Schwab RIA Talent Study Reveals Industry Attributes That Attract Advisors to RIA Profession investment picks
2014/10/2
Three out of four people are not aware that dense breast tissue increases a woman’s risk of developing breast cancer, 1, 2 according to a new global study from GE Healthcare exploring perspectives on breast cancer with an emphasis on understanding awareness around dense breast tissue and the most common symptoms of breast cancer.
Sign-up for GE Healthcare Study: Most People Unaware that Women with High Breast Density are 4 to 5 Times More Likely to Develop Breast Cancer 1 2 investment picks
MM-398 in combination with 5-fluorouracil and leucovorin shows statistically significant improvement in overall survival, progression free survival and overall response rate in patients with post-gemcitabine metastatic pancreatic cancer CAMBRIDGE, Mass., June 25, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced detailed results from NAPOLI-1, a large, randomized, three-arm Phase 3 study of MM-398, a nanoliposomal encapsulation of irinotecan, in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy.
Sign-up for Merrimack Pharmaceuticals Presents Data From Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer investment picks
NOVATO, Calif., June 24, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE) , a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a multiple-dose study, conducted by Kyowa Hakko Kirin Pharma, Inc. (KKP), of the investigational anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, bone pain, fractures, and muscle weakness.
Sign-up for Ultragenyx Announces Results From Phase 1/2 Study of KRN23 in X-linked Hypophosphatemia in Adults investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Research Study
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Storage  |  Next: Research Subscription